Quarterly ResultJul 6, 2026, 04:16 PM
RxSight Q2 Preliminary Revenue $32-34M; FY26 Guidance Revised
AI Summary
RxSight, Inc. announced preliminary financial results for the second quarter of 2026, expecting total revenue of $32-34 million, including $5-7 million from the Alcon strategic collaboration. The company also updated its full-year 2026 guidance, lowering sales expectations to $110-120 million but raising gross margin guidance to 73-75%. Despite facing commercial headwinds, RxSight highlighted its product pipeline, including next-generation LAL lenses, and its collaboration with Alcon for Presbyopia-Correcting Intraocular Lenses.
Key Highlights
- Preliminary Q2 2026 total revenue expected at $32-34 million.
- Revised FY 2026 total revenue guidance lowered to $140-160 million.
- Revised FY 2026 sales guidance lowered to $110-120 million.
- Revised FY 2026 gross margin guidance raised to 73-75%.
- Cash, cash equivalents, and short-term investments totaled $209 million as of June 30, 2026.
- Strategic collaboration with Alcon to develop light-adjustable Presbyopia-Correcting IOLs.
- Pipeline updates include next-generation LAL, LAL+, and LAL Toric lenses.
Price Impact
More from RXST